4.8 Article

In vivo effects of a GPR30 antagonist

Journal

NATURE CHEMICAL BIOLOGY
Volume 5, Issue 6, Pages 421-427

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nchembio.168

Keywords

-

Funding

  1. NIH [CA118743, CA127731, R37 NS18710, HL90804]
  2. Oxnard and Stranahan Foundations
  3. University of New Mexico Center for Molecular Discovery [NIH U54 MH084690]
  4. New Mexico Tobacco Settlement fund
  5. New Mexico Cowboys for Cancer Research

Ask authors/readers for more resources

Estrogen is central to many physiological processes throughout the human body. We have previously shown that the G protein-coupled receptor GPR30 (also known as GPER), in addition to classical nuclear estrogen receptors (ER alpha and ER beta), activates cellular signaling pathways in response to estrogen. In order to distinguish between the actions of classical estrogen receptors and GPR30, we have previously characterized G-1 (1), a selective agonist of GPR30. To complement the pharmacological properties of G-1, we sought to identify an antagonist of GPR30 that displays similar selectivity against the classical estrogen receptors. Here we describe the identification and characterization of G15 (2), a G-1 analog that binds to GPR30 with high affinity and acts as an antagonist of estrogen signaling through GPR30. In vivo administration of G15 revealed that GPR30 contributes to both uterine and neurological responses initiated by estrogen. The identification of this antagonist will accelerate the evaluation of the roles of GPR30 in human physiology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available